KLH 2109

Drug Profile

KLH 2109

Alternative Names: KLH-2109; OBE 2109

Latest Information Update: 05 May 2017

Price : $50

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Kissei Pharmaceutical; ObsEva
  • Class Antihormones
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uterine leiomyoma
  • Phase II Endometriosis

Most Recent Events

  • 25 Apr 2017 Phase-III clinical trials in Uterine leiomyoma (Combination therapy, Monotherapy) in USA (PO) (NCT03070899)
  • 25 Apr 2017 ObsEva initiates enrolment in the PRIMEROSE 2 phase III trial for Uterine leiomyoma (Combination therapy, Monotherapy)
  • 08 Mar 2017 ObsEva plans the PRIMROSE 2 phase III trial for Uterine leiomyoma (Monotherapy, Combination therapy) (NCT03070951)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top